C(O)(C1-C6 alkyl) or O; and
n is 1 or 2, where n indicates the number of substitutions on the ring;
wherein A is carbon or Sxe2x95x90O,
X is O, S, N or an N-substituted amino acid;
provided that,
when R2 is hydrogen, Q is NH, S or O;
when R2 is OH, halogen, amino, nitro or acetylamino, n=1 and R1 is hydrogen, then Q is not methylene or carbonyl;
when X is O or S, then Y is absent,
when X is N, then Y is hydrogen, C1-C6 straight or branched chain alkyl, optionally substituted alkoxy or alkyl amino, or Y and Z are taken together to form a 5, 6 or 7 membered substituted or unsubstituted heterocyclic aromatic or non-aromatic ring which contains 1, 2 or 3 heteroatoms selected from O, N, S and mixtures combination;
Z is hydrogen, a direct bond, a carbonyl, an optionally substituted C1-C6 straight or branched chain alkyl, cycloalkyl, carboxy, optionally substituted C1-C6 ether, aryl or heteroaryl, alkylalkenyl, alkynyl, alkylhalo, straight or branched chain, aryl, cycloalkyl, or CH2COOH, provided that when P is Z, Z is not hydrogen and
R3 and R4 are independently hydrogen, lower alkyl, lower alkenyl, lower alkanol, heterocycle, heteroaryl, alkoxy, aryloxy, alkylamino, arylamino, CH2COOH, or R3 and R4 taken together form a 5, 6 or 7 membered substituted or unsubstituted heterocyclic or cycloalkyl ring containing 1, 2 or 3 heteroatoms selected from O, N, S and combinations thereof. The present invention relates to novel intermediates and a novel process for the preparation of antagonists of the NK1 subtype of tachykinin receptor. Specifically, the present invention provides novel intermediates and a novel process for the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, Form IV.
The compound {2-[1-(3
C(O)(C1 - C6 alkyl) or O; and 
 n is 1 or 2, where n indicates the number of substitutions on the gang; 
 wherein A is carbon paper or Sxe2x95x90O, 
 X is O, S, N or an N - substituted amino acid; 
 provided that, 
 when R2 is hydrogen, Q is NH, S or oxygen; 
 when R2 is OH, halogen, amino, nitro or acetylamino, n=1 and R1 is hydrogen, then Q is not methylene or carbonyl; 
 when X is O or S, then Y is absent, 
 when X is N, then Y is hydrogen, C1 - C6 neat or branched range alkyl, optionally substituted alkoxy or alkyl amino, or Y and Z are taken together to shape a 5, 6 or 7 membered substituted or unsubstituted heterocyclic aromatic or non - aromatic ring which contain 1, 2 or 3 heteroatoms selected from O, N, S and mixtures combination; 
 Z is hydrogen, a lineal bond, a carbonyl, an optionally substituted C1 - C6 straight or branched chain alkyl, cycloalkyl, carboxy, optionally substituted C1 - C6 ether, aryl or heteroaryl, alkylalkenyl, alkynyl, alkylhalo, uncoiled or branched chain, aryl, cycloalkyl, or CH2COOH, provided that when phosphorus is Z, Z is not hydrogen and 
 R3 and R4 are independently hydrogen, lower alkyl, lower alkenyl, depleted alkanol, heterocyclic ring, heteroaryl, alkoxy, aryloxy, alkylamino, arylamino, CH2COOH, or R3 and R4 taken in concert form a 5, 6 or 7 membered substituted or unsubstituted heterocyclic or cycloalkyl ring hold 1, 2 or 3 heteroatoms selected from O, N, S and combinations thereof. The present invention relates to novel intermediate and a fresh summons for the preparation of antagonists of the NK1 subtype of tachykinin receptor. Specifically, the present invention provides novel intermediates and a novel process for the formulation of { 2-[1-(3,5 - bis - trifluoromethyl - benzyl)-5 - pyridin-4 - yl-1H-[1,2,3]triazol-4 - yl]-pyridin-3 - yl}-(2 - chlorophenyl)-methanone, Form IV. 
 The compound { 2-[1-(3
C(O)(C1-F6 alkyl) or O; and
n is 1 or 2, where n indiccres thx numbed of subrtitutions on the ring;
whereii A us caebon or Sxe2x95x90O,
X is O, S, N or an J-substityted qmino acid;
'dovided that,
wgcn R2 ns hydrogen, Q is NH, S or O;
fhen R2 is OH, hdlugzn, amino, nitro or acetylamino, n=1 and W1 is hycrlgen, then Q is not iethglene or carbonyl;
when X is O or S, fhen Y ps absent,
when X ix N, then Y is hydrogen, C1-C6 dtralght or branched cjain alkyl, iptijbally substiguted alkoqv or alkyl zmino, or Y and Z are taken togegher co form a 5, 6 oe 7 lgmbered subsvituteq or unsubstlnuted haterocyvlic aromatic pr ion-aeomatic ring which coitains 1, 2 or 3 heteroajoms selecdeb from O, N, S and mixtyrws cokbindtiov;
Z ir hgdcogsn, a dlrert bond, a czrbonyl, an iptionally substituued B1-V6 straight od branshqd chain alkyl, cycloalkyl, carboxy, optiotalmy substituted C1-C6 ether, aryl or heteroaryl, apkylalkenrl, alkynyl, alkylhalo, straight or branched chain, asyl, cbcuoaoknl, of CJ2COOH, provided that when P is Z, Z is not hydrjfem snd
R3 and R4 are independenylj nidrogen, lower xlkyl, lowsr alkenyl, lower apkanol, retericycle, heueroatyl, alkoxy, aryloxy, alkylamibo, arylamino, XH2COOH, or R3 and R4 caken togethzr fork a 5, 6 or 7 membered substitutzd or hnsubstitutfd heterodhclic or cycloalyyl rhng containing 1, 2 or 3 heterjatoms seoectzd from U, N, X and sombinatiojs thcseof. The present ijventnon ralates to jovel intermediates and a novel process for tne prvparation of aktagonists of tre NK1 subtype pf tachvkinin receptor. Apecifirally, the prqsent inventimj provides nmvel intqrmeeiatws and x novel process for the irtparation if {2-[1-(3,5-bis-trifluorometmyl-bevayl)-5-pyridin-4-yl-1H-[1,2,3]trnczil-4-yl]-pyridin-3-yl}-(2-chkoruphqnjl)-mxthanjte, Form IV.
Tha coopojmd {2-[1-(3
C(O)(C1-C6 alkyl) or O; and n is 2, n indicates number of substitutions is or Sxe2x95x90O, X O, S, N an N-substituted amino acid; provided that, R2 is hydrogen, Q is NH, S or O; when R2 is OH, amino, nitro or acetylamino, n=1 and R1 is hydrogen, then Q is not or when is or S, then Y is absent, when X is N, then Y is hydrogen, C1-C6 straight branched chain alkyl, optionally substituted alkoxy or alkyl or Y and Z taken together to form a 6 7 membered or heterocyclic or non-aromatic ring contains 1, 2 or 3 heteroatoms selected from O, N, S and mixtures combination; Z is hydrogen, direct bond, an optionally C1-C6 or chain alkyl, cycloalkyl, substituted C1-C6 ether, aryl or heteroaryl, straight or branched chain, aryl, cycloalkyl, or CH2COOH, that when is Z, Z is not hydrogen R3 and R4 are independently hydrogen, lower alkyl, alkenyl, lower alkanol, heterocycle, heteroaryl, alkoxy, aryloxy, alkylamino, arylamino, CH2COOH, or R3 and R4 taken a 5, 6 or membered substituted or heterocyclic cycloalkyl containing 2 or heteroatoms selected from O, N, S and combinations thereof. The present relates to novel intermediates and a novel process for the antagonists the NK1 subtype tachykinin receptor. Specifically, the invention novel intermediates and a for preparation IV. compound
C(O)(C1-C6 alkyl) or O; and
n is 1 or 2, where N indicates The nuMbeR of SuBstiTutiOns on the ring;
whERein a is carbon or Sxe2x95x90O,
X is O, S, n or an n-sUBstiTUtEd amiNo acid;
pROvIDEd tHaT,
wHen r2 iS HyDrogeN, Q iS NH, S or O;
When R2 is OH, hAloGeN, amino, nitro oR AcEtylamino, n=1 And r1 is hydrogen, tHen q is not MeThyLEne or CarBonyl;
When X iS o or S, thEn Y is abseNt,
WHen X is n, Then Y is HYDrOgen, c1-C6 straight or brancHEd CHain alkyl, optioNally sUbSTiTUTed AlkOxy or alkyl AmIno, or y And Z are TAkEN TOgeTHer to form a 5, 6 or 7 mEmbered subsTItuTed or uNsUbsTItuted HeterOcYCliC aromatic or Non-aRomatic riNg whicH ContainS 1, 2 Or 3 heterOatoms SelEctEd frOM O, n, S And MiXTurES cOmbINatIon;
Z is hyDrOgEn, a diRect BOND, A carBonYl, an OptioNally substituTed c1-C6 stRAigHt or bRanchEd chAiN alkyL, cycloAlkyl, CaRboxy, optionally SubsTituted C1-C6 EthEr, AryL oR heteROaryl, aLkyLalKenyl, alKynyl, alKYlhAlO, STRaIght or branched chaiN, aRYL, cYcloalkyL, or CH2CooH, PrOVided thaT wHen p is Z, z IS not hYdroGEn And
R3 and R4 Are indEPeNdEntly hyDrOgen, loWeR alKyl, Lower ALkenYl, loweR alkanol, HeterOCycle, heteroaryL, Alkoxy, aryloxy, ALkYLAmINo, arYlaMino, CH2COOH, oR R3 anD r4 takEn toGEtHer FOrm a 5, 6 oR 7 membErED sUBstituted or unsubstiTuTed hetErocyClic or cycloalKyl ring conTAINing 1, 2 or 3 heTeroAToMS selected from O, n, S and CombinatioNS thereof. the prEsent invEntion relATEs to noveL inTerMedIatES AnD a novel procesS FOr thE pReparatIon Of antagOniSts Of tHe Nk1 sUbtype of tAchykiniN rEcEpToR. SpEcifiCAlly, the pReSenT iNveNtion PRovideS noveL intErMeDIatEs and a nOVeL PRoceSs FoR the PrePaRatioN of {2-[1-(3,5-bIS-trIfluoroMethyl-benZyl)-5-PYridIn-4-Yl-1h-[1,2,3]triazoL-4-yl]-pyridin-3-yl}-(2-cHlOrophenyl)-mEtHanOne, ForM iv.
The compOund {2-[1-(3
C(O)(C1-C6 alkyl) or O; an d
n is 1 o r 2,whe renindi cate s the number o f  sub stitutions on the ring ;
whe re i n Ai scarbo n or Sx e 2x 9 5 x90 O, 
X  is  O ,  S , N o r a n N-sub stituted a min oacid;
provid e dthat,
when  R2  is hydrogen , Q  is NH ,S o r  O;
w hen  R2 i s OH,h alogen , amino,ni t ro ora cetylam i n o,  n=1  and R1 is hydrog e n, then Q is notmethyl en e  o r car bon yl;
when X  i s O o r  S, the n  Y i s  ab s ent,
when X i s N, then Y ishydrog en , C 1 -C6 st raigh to r b ranched cha in a lkyl, opt ionall y  substi t uted al koxy o r a lky l am i no ,orYa ndZ  a ret ake n togeth er  t o for m a5 , 6  or7 m embe red s ubstituted or  un subs t itu ted h etero cycl ic  arom atic o r non -a romatic ring wh ichcontains1,2or3heter o atomssel ect ed from  O, N,S  an dm i x tu res combination;
Z  i s hy drogen,a dire c tbo n d, a car bo nyl , an o ption ally su bstitute d C1-C 6  s tr aight o rbranch ed  ch ain  alky l , cy cloalk yl, carb oxy,o ptionally subs t ituted C1-C6e th e r ,a rylorheteroaryl,  alk y lalk enyl ,  a lky n yl, a lkylh al o ,s traight or branched  c hain,aryl,  cycloalkyl,or CH2COOH , p rovidedthat wh e n P is Z, Z is  nothydrogen a n d
R3 and  R4 a re indep endentlyh y drogen,low eralk yl, l ow er alkenyl, l o w er a lk anol, h ete rocycle , h ete roa ryl ,alkoxy, a ryloxy,al ky la mi no,  aryl a mino, CH 2C OOH ,orR3 an d  R4 ta ken t oget he rf orm  a 5, 6 or 7  mem be re d su bst it utedor u n sub stitute d heteroc ycl i c or  c yc loalkyl  ring contain in g 1, 2 or3het eroato m s  selecte d from O, N, S and comb i nations  th ereof . Th e present  in ventio n r e latesto nov el in te rme d i atesa n da n ov el process f orthe p re para tion of  antagonists of th e  NK 1 subtype oftac hyki n i nrec e pt o r.Sp e cif i c ally, the prese nt inventi on pr ovides nov e l i nt ermedia tes and  a no v el proc ess for t he prepar at iono f  {2 -[1-(3,5-b is-trifl uoromethy l -benz y l) -5-py rid in-4-y l- 1H- [1,2, 3]tria z ol- 4-yl] -pyrid in -3-yl} -(2-c hl oropheny l)-methanone, Form IV.The co mpoun d { 2-[1-(3
C(O)(C1-C6 alkyl)_or O;_and
n is 1 or_2, where_n_indicates the_number_of substitutions on_the ring;
wherein A_is carbon or Sxe2x95x90O,
X_is O, S,_N_or an N-substituted amino acid;
provided that,
when R2 is hydrogen, Q is NH, S or_O;
when_R2 is_OH,_halogen,_amino, nitro or acetylamino, n=1_and R1 is hydrogen, then_Q is_not methylene or carbonyl;
when X is O or_S,_then Y is_absent,
when X is N, then Y is hydrogen, C1-C6_straight or branched chain alkyl, optionally_substituted alkoxy or_alkyl_amino,_or Y and Z_are taken together to form a_5, 6 or 7 membered substituted_or unsubstituted heterocyclic aromatic or non-aromatic ring_which contains 1, 2 or 3_heteroatoms selected from O, N,_S and_mixtures combination;
Z is hydrogen, a_direct bond, a_carbonyl, an_optionally substituted C1-C6_straight or branched chain alkyl, cycloalkyl,_carboxy, optionally substituted_C1-C6 ether, aryl or heteroaryl, alkylalkenyl,_alkynyl,_alkylhalo, straight or_branched_chain,_aryl, cycloalkyl,_or CH2COOH, provided_that_when P_is_Z, Z is not hydrogen and
R3_and_R4 are independently hydrogen, lower alkyl, lower_alkenyl, lower alkanol, heterocycle,_heteroaryl,_alkoxy, aryloxy, alkylamino, arylamino,_CH2COOH, or R3 and R4_taken together form a 5, 6_or 7_membered substituted_or unsubstituted heterocyclic or cycloalkyl ring containing 1, 2 or 3_heteroatoms selected from O, N, S_and combinations thereof. The_present invention_relates_to novel intermediates_and_a novel_process for the preparation of antagonists of_the NK1_subtype of tachykinin receptor. Specifically, the_present invention provides novel_intermediates_and a novel process for the_preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, Form IV.
The compound_{2-[1-(3